410 related articles for article (PubMed ID: 33983833)
21. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
Saganelidze K; Kavtaradze N
Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
[TBL] [Abstract][Full Text] [Related]
22. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
23. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
24. Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
Wilcox NS; Rotz SJ; Mullen M; Song EJ; Ky Hamilton B; Moslehi J; Armenian SH; Wu JC; Rhee JW; Ky B
Circ Res; 2022 Feb; 130(4):632-651. PubMed ID: 35175846
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
26. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management.
Jerusalem G; Lancellotti P; Kim SB
Breast Cancer Res Treat; 2019 Sep; 177(2):237-250. PubMed ID: 31165940
[TBL] [Abstract][Full Text] [Related]
27. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.
Florido R; Smith KL; Cuomo KK; Russell SD
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939718
[No Abstract] [Full Text] [Related]
29. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Maurea N; Spallarossa P; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S93-S104. PubMed ID: 27183530
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of anthracycline-mediated cardiotoxicity and preventative strategies in women with breast cancer.
Varghese SS; Eekhoudt CR; Jassal DS
Mol Cell Biochem; 2021 Aug; 476(8):3099-3109. PubMed ID: 33835331
[TBL] [Abstract][Full Text] [Related]
31. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
33. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.
Wouters KA; Kremer LC; Miller TL; Herman EH; Lipshultz SE
Br J Haematol; 2005 Dec; 131(5):561-78. PubMed ID: 16351632
[TBL] [Abstract][Full Text] [Related]
34. Ocular toxicities of MEK inhibitors and other targeted therapies.
Stjepanovic N; Velazquez-Martin JP; Bedard PL
Ann Oncol; 2016 Jun; 27(6):998-1005. PubMed ID: 26951625
[TBL] [Abstract][Full Text] [Related]
35. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of Contemporary Breast Cancer Treatments.
Lee Chuy K; Yu AF
Curr Treat Options Oncol; 2019 May; 20(6):51. PubMed ID: 31073788
[TBL] [Abstract][Full Text] [Related]
37. [Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines].
Fernandes RRA; Vianna CMM; Freitas PG; Guerra RL; Corrêa FM
Cad Saude Publica; 2019 Sep; 35(9):e00191518. PubMed ID: 31531521
[TBL] [Abstract][Full Text] [Related]
38. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
Launay-Vacher V; Aapro M; De Castro G; Cohen E; Deray G; Dooley M; Humphreys B; Lichtman S; Rey J; Scotté F; Wildiers H; Sprangers B
Ann Oncol; 2015 Aug; 26(8):1677-84. PubMed ID: 25735315
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
40. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]